- Home
- SKIN vs RDIB Comparison
SKIN vs RDIB Comparison
Compare SKIN & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- RDIB
- Stock Information
- Founded
- SKIN 1997
- RDIB 1937
- Country
- SKIN United States
- RDIB United States
- Employees
- SKIN N/A
- RDIB N/A
- Industry
- SKIN Package Goods/Cosmetics
- RDIB Movies/Entertainment
- Sector
- SKIN Consumer Discretionary
- RDIB Consumer Discretionary
- Exchange
- SKIN Nasdaq
- RDIB Nasdaq
- Market Cap
- SKIN 164.1M
- RDIB 140.2M
- IPO Year
- SKIN N/A
- RDIB N/A
- Fundamental
- Price
- SKIN $1.34
- RDIB $7.02
- Analyst Decision
- SKIN Hold
- RDIB
- Analyst Count
- SKIN 5
- RDIB 0
- Target Price
- SKIN $2.50
- RDIB N/A
- AVG Volume (30 Days)
- SKIN 730.8K
- RDIB 12.3K
- Earning Date
- SKIN 03-12-2025
- RDIB 05-14-2025
- Dividend Yield
- SKIN N/A
- RDIB N/A
- EPS Growth
- SKIN N/A
- RDIB N/A
- EPS
- SKIN N/A
- RDIB N/A
- Revenue
- SKIN $334,294,000.00
- RDIB $210,527,000.00
- Revenue This Year
- SKIN $1.93
- RDIB N/A
- Revenue Next Year
- SKIN $12.41
- RDIB $18.29
- P/E Ratio
- SKIN N/A
- RDIB N/A
- Revenue Growth
- SKIN N/A
- RDIB N/A
- 52 Week Low
- SKIN $0.91
- RDIB $5.78
- 52 Week High
- SKIN $4.48
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- SKIN 45.76
- RDIB 46.06
- Support Level
- SKIN $1.25
- RDIB $6.06
- Resistance Level
- SKIN $1.45
- RDIB $12.30
- Average True Range (ATR)
- SKIN 0.11
- RDIB 1.08
- MACD
- SKIN 0.01
- RDIB -0.18
- Stochastic Oscillator
- SKIN 34.29
- RDIB 15.38
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.